U.S. markets open in 5 hours 47 minutes
  • S&P Futures

    -4.00 (-0.08%)
  • Dow Futures

    -84.00 (-0.21%)
  • Nasdaq Futures

    +25.00 (+0.14%)
  • Russell 2000 Futures

    +1.40 (+0.07%)
  • Crude Oil

    +0.27 (+0.34%)
  • Gold

    -2.90 (-0.14%)
  • Silver

    -0.08 (-0.35%)

    +0.0006 (+0.05%)
  • 10-Yr Bond

    0.0000 (0.00%)
  • Vix

    +0.38 (+2.90%)

    +0.0015 (+0.12%)

    +0.2250 (+0.15%)
  • Bitcoin USD

    +3,604.61 (+5.85%)
  • CMC Crypto 200

    0.00 (0.00%)
  • FTSE 100

    -12.94 (-0.17%)
  • Nikkei 225

    +198.41 (+0.50%)

Peak Pharma and Canna-Pet(R) Enjoy Outstanding Product Launch Success

New MaxCBD Canna-Biscuits Sell Out in Under 72 Hours; Manufacturing and Restocking Efforts Underway

BOULDER, CO--(Marketwired - Apr 13, 2015) - Peak Pharmaceuticals, Inc. (OTCQB: PKPH) ("Peak Pharma" or the "Company"), and Canna-Pet, a leading innovator of non-prescription cannabinoid products for animals, were thrilled to announce today that their recent MaxCBD biscuit product launch sold out in under 72 hours.

The new MaxCBD Canna-Biscuits for dogs offer up to six times the CBD of the Company's standard Canna-Biscuit product line, and the overwhelming popularity of the launch exceeded expectations. The initial limited production run of the Max CBD biscuits was designed as a test marketing opportunity and the Company believes the test proved the market for this product. As a result, the company now plans to make this a regular part of its product lineup. Manufacturing of additional inventory is already underway, and interested consumers are invited to sign up at, for email notifications and news from the company regarding new product developments and the timeline for availability of MaxCBD Canna-Biscuits from our warehouse.

The launch of this all new product is a testament to the collaborative efforts between Peak Pharma and Canna-Pet LLC, and although just a small element of the Company's strategic plan, it underscores the company's focus on and ability to execute. The Company's primary goal remains bringing to market a hemp-based product for humans. The industrial and commercial intelligence the Company is currently gathering through its veterinary product activities are positively impacting the Company's timeline for achieving the goal of testing and launch of its first hemp-based product for humans before year end.

Initial success of the Maximum CBD Canna-Biscuits is attributed to consumers who seek the highest CBD and cannabinoid content for their pets. The product is formulated with Canna-Pet® to deliver the entire cannabinoid profile of hemp, including CBD. All Canna-Biscuits are made in the USA, with 100% organic, non-GMO, human grade food ingredients and the MaxCBD biscuit product will shortly be available on the website. When used as directed, the bite-sized treats are easy to administer at home or on the go.

Company CEO, Dr. Soren Mogelsvang notes, "We are delighted that the new MaxCBD Canna-Biscuits were received so enthusiastically. We felt a small production run was the best way to assess consumer interest, and given the response, we want to assure our customers that new product will be available as quickly as possible. A quality product, such as these biscuits, requires a few short weeks to deliver and we appreciate your patience and understanding. Attention to quality is a hallmark at Peak Pharma, and an integral part of the process aimed at bringing new human products to market later this year."

About Peak Pharmaceuticals, Inc. (OTCQB: PKPH)
Peak Pharmaceuticals, Inc. specializes in the development, manufacturing, sales and marketing of pharmaceutical-grade, hemp-based supplement products for the human and animal health markets. The company aims to become a global leader in the research, development, sales and marketing of hemp and cannabinoid based supplements. For more information visit and follow us on Facebook, Twitter and LinkedIn.

About Canna-Pet® Products for Pet Health
Canna-Pet® offers non-prescription CBD products for domesticated animals such as cats and dogs. Canna-Pet® is the culmination of years of research and development to provide the benefits of hemp-based CBD and cannabinoids without the "high" typically associated with psychoactive components. The company uses non-GMO hemp as starting material and all products are proudly manufactured in the USA. In addition to CBD, Canna-Pet products differ from its competitors through the use of proprietary ratios of hemp derived cannabinoids and terpenes. Canna-Pet® is a trademarked, leading producer of safe, hemp-based, cannabidiol (CBD) containing products, which are available under an exclusive commercial license agreement with Peak Pharmaceuticals, Inc. (OTCQB: PKPH). Order online at: or under "Pet Supplies" on Amazon, and join us on Facebook and Twitter.

Additional details of Peak Pharmaceuticals business, finances, appointments, risks and agreements can be found as part of the Company's continuous public disclosure as a reporting issuer with the Securities and Exchange Commission ("SEC") available at For more information please visit

Safe Harbor Statement
Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Any forward-looking statements contained herein are based on current expectations, but are subject to a number of risks and uncertainties. The factors that could cause actual future results to differ materially from current expectations include, but are not limited to, risks and uncertainties relating to the availability of additional funding; the early-stage nature of the industry sector; regulatory changes affecting the sale, transport or consumption of Cannabidiol or hemp based products by humans or animals; commercial impacts to the Company's business, related agreements, product development, marketing and distribution plans and strategies. These and other factors are identified and described in more detail in the Company's filings with the SEC, including, the Company's current reports on Form 8-K. The Company does not undertake to update these forward-looking statements. FDA Disclosure: The statements in this news release have not been evaluated by the U.S. Food and Drug Administration (USFDA). The products mentioned herein are not intended for human consumption, or to diagnose, treat, cure, or prevent any disease. Information contained or made available through the Canna-Pet™ website or affiliate sites is not intended to constitute or substitute for legal or veterinary advice.